全文获取类型
收费全文 | 243篇 |
免费 | 16篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 2篇 |
妇产科学 | 4篇 |
基础医学 | 35篇 |
口腔科学 | 3篇 |
临床医学 | 15篇 |
内科学 | 61篇 |
皮肤病学 | 2篇 |
神经病学 | 12篇 |
特种医学 | 22篇 |
外科学 | 27篇 |
综合类 | 1篇 |
预防医学 | 9篇 |
眼科学 | 2篇 |
药学 | 9篇 |
肿瘤学 | 52篇 |
出版年
2024年 | 1篇 |
2023年 | 2篇 |
2022年 | 4篇 |
2021年 | 8篇 |
2020年 | 7篇 |
2019年 | 6篇 |
2018年 | 11篇 |
2017年 | 8篇 |
2016年 | 12篇 |
2015年 | 11篇 |
2014年 | 11篇 |
2013年 | 10篇 |
2012年 | 17篇 |
2011年 | 9篇 |
2010年 | 8篇 |
2009年 | 7篇 |
2008年 | 8篇 |
2007年 | 10篇 |
2006年 | 16篇 |
2005年 | 13篇 |
2004年 | 3篇 |
2003年 | 9篇 |
2002年 | 10篇 |
2001年 | 1篇 |
2000年 | 2篇 |
1999年 | 2篇 |
1998年 | 7篇 |
1997年 | 2篇 |
1996年 | 1篇 |
1995年 | 1篇 |
1994年 | 1篇 |
1993年 | 1篇 |
1992年 | 9篇 |
1991年 | 6篇 |
1990年 | 4篇 |
1989年 | 6篇 |
1988年 | 1篇 |
1987年 | 2篇 |
1986年 | 2篇 |
1985年 | 3篇 |
1984年 | 2篇 |
1983年 | 1篇 |
1982年 | 1篇 |
1977年 | 1篇 |
1970年 | 1篇 |
1968年 | 2篇 |
排序方式: 共有260条查询结果,搜索用时 125 毫秒
71.
72.
Elastase Is the Only Human Neutrophil Granule Protein That Alone Is Responsible for In Vitro Killing of Borrelia burgdorferi 总被引:1,自引:0,他引:1 下载免费PDF全文
Rodolfo Garcia Laura Gusmani Rossella Murgia Corrado Guarnaccia Marina Cinco Giandomenico Rottini 《Infection and immunity》1998,66(4):1408-1412
Phagocytosis of Borrelia burgdorferi by human polymorphonuclear leukocytes triggers oxygen-dependent and -independent mechanisms of potentially cidal outcome. Nevertheless, no factor or process has yet been singled out as being borreliacidal. We have studied the B. burgdorferi-killing ability of the myeloperoxidase-H2O2-chloride system and that of primary and secondary granule components in an in vitro assay. We found that neither secondary granule acid extracts nor the chlorinating system could kill these microorganisms, while primary granule extracts were effective. The Borrelia-killing factor was purified to homogeneity and demonstrated to be elastase. Its cidal activity was found to be independent of its proteolytic activity. 相似文献
73.
74.
Giandomenico Roviello Karol Polom Roberto Petrioli Luigi Marano Daniele Marrelli Giovanni Paganini Vinno Savelli Daniele Generali Lorenzo De Franco Andrea Ravelli Franco Roviello 《Tumour biology》2016,37(1):127-140
Gastric cancer (GC) is the second leading cause of cancer-related death, and despite having improved treatment modalities over the last decade, for most patients, only modest improvements have been seen in overall survival. Recent progress in understanding the molecular biology of GC and the related signaling pathways offers, from the clinical point of view, promising advances for selected groups of patients. In the past, targeted therapies have significantly impacted the treatment strategy of several common solid tumors such as breast, colorectal, and lung cancers. Unfortunately, translational and clinical research shows fewer encouraging targeted treatments with regards to the GC. To date, only two monoclonal antibodies (mAb), named trastuzumab and ramucirumab, are approved for the treatment of advanced GC, suggesting that in GC, maybe more than in other cancers, effective targeted therapy requires patient selection based on precise predictive molecular biomarkers. The aim of this review is to summarize the available data on the clinical advantages offered by the use of mAbs in the treatment of advanced/metastatic GC. Future perspective is also discussed. 相似文献
75.
Gridelli B Vizzini G Pietrosi G Luca A Spada M Gruttadauria S Cintorino D Amico G Chinnici C Miki T Schmelzer E Conaldi PG Triolo F Gerlach JC 《Liver transplantation》2012,18(2):226-237
Although hepatic cell transplantation (CT) holds the promise of bridging patients with end-stage chronic liver failure to whole liver transplantation, suitable cell populations are under debate. In addition to hepatic cells, mesenchymal stem cells (MSCs) and hematopoietic stem cells (HSCs) are being considered as alternative cell sources for initial clinical cell work. Fetal liver (FL) tissue contains potential progenitors for all these cell lineages. Based on the collagenase incubation of tissue fragments, traditional isolation techniques yield only a fraction of the number of available cells. We report a 5-step method in which a portal vein in situ perfusion technique is used for tissue from the late second trimester. This method results in the high viabilities known for adult liver vascular perfusion, addresses the low cell yields of conventional digestion methods, and reduces the exposure of the tissue to collagenase 4-fold. We used donated tissue from gestational weeks 18 to 22, which yielded 1.8 ± 0.7 × 10(9) cells with an average viability of 78%. Because HSC transplantation and MSC transplantation are of interest for the treatment of hepatic failure, we phenotypically confirmed that in addition to hepatic progenitors, the resulting cell preparation contained cells expressing typical MSC and HSC markers. The percentage of FL cells expressing proliferation markers was 45 times greater than the percentage of adult hepatocytes expressing these markers and was comparable to the percentage of immortalized HepG2 liver hepatocellular carcinoma cells; this indicated the strong proliferative capacity of fetal cells. We report a case of human FL CT with the described liver cell population for clinical end-stage chronic liver failure. The patient's Model for End-Stage Liver Disease (MELD) score improved from 15 to 10 within the first 18 months of observation. In conclusion, this human FL cell isolation protocol may be of interest for further clinical translation work on the development of liver cell-based therapies. 相似文献
76.
77.
Luatti S Castagnetti F Marzocchi G Baldazzi C Gugliotta G Iacobucci I Specchia G Zanatta L Rege-Cambrin G Mancini M Abruzzese E Zaccaria A Grimoldi MG Gozzetti A Ameli G Capucci MA Palka G Bernasconi P Palandri F Pane F Saglio G Martinelli G Rosti G Baccarani M Testoni N;Gruppo Italiano Malattie Ematologiche dell'Adulto 《Blood》2012,120(4):761-767
Additional chromosomal abnormalities (ACAs) in Philadelphia-positive cells have been reported in ~ 5% of patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CP). Few studies addressing the prognostic significance of baseline ACAs in patients treated with imatinib have been published previously. The European LeukemiaNet recommendations suggest that the presence of ACAs at diagnosis is a "warning" for patients in early CP, but there is not much information about their outcome after therapy with tyrosine kinase inhibitors. To investigate the role of ACAs in early CP CML patients treated with imatinib mesylate, we performed an analysis in a large series of 559 patients enrolled in 3 prospective trials of the Gruppo Italiano Malattie Ematologiche dell'Adulto Working Party on CML: 378 patients were evaluable and ACAs occurred in 21 patients (5.6%). The overall cytogenetic and molecular response rates were significantly lower and the time to response was significantly longer in patients with ACAs. The long-term outcome of patients with ACAs was inferior, but the differences were not significant. The prognostic significance of each specific cytogenetic abnormality was not assessable. Therefore, we confirm that ACAs constitute an adverse prognostic factor in CML patients treated with imatinib as frontline therapy. 相似文献
78.
79.
Giandomenico Roviello Edoardo Francini Armando Perrella Letizia Laera Maria Antonietta Mazzei Susanna Guerrini Franco Roviello Daniele Marrelli Roberto Petrioli 《Cancer biology & therapy》2015,16(4):493-497
Bevacizumab and Tamoxifen are valid therapeutic options for metastatic breast cancer (mBC) patients. In this report, we describe a 47 year old woman with mBC successfully treated with a maintenance therapy with Bevacizumab+Tamoxifen. A maintenance approach using 2 different drugs with different targets and mechanism of action, such as anti-angiogenic and anti-hormonal treatment is particularly intriguing because they affect different pathways involved in mBC progression. Further studies including a large number of patients are needed, in order to select women who could benefit from this maintenance approach. 相似文献